(March 24, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that a jury in Delaware issued a verdict in a retrial of patent litigation between Boston Scientific and Johnson & Johnson (NYSE: JNJ). The jury found that a single claim of Johnson & Johnson's Palmaz patent was valid and infringed by the NIR® stent, which was designed and manufactured by Medinol Ltd. and formerly sold by Boston Scientific. The jury only determined liability; any monetary damages will be determined in a later hearing. In addition, there are likely to be significant post-verdict motions and hearings, as well as an appeal of the decision. The court has not yet set a post-verdict schedule.

Boston Scientific no longer markets or sells the NIR stent. The jury's findings will not affect Boston Scientific's ability to sell its market-leading TAXUS® Express™ paclitaxel-eluting stent system or its next-generation TAXUS® Liberté™ paclitaxel-eluting stent system.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation, the commercialization of new technologies, competitive offerings, intellectual property and other factors described in the Company's filings with the Securities and Exchange Commission.